Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| SCCHO-ATP171 | Human | CHO/Human CD79B Stable Cell Line | |||
| CDB-HP2H6 | Human | PE-Labeled Human CD79B Protein, His Tag (Site-specific conjugation) |  |
||
| CDB-C82E5 | Cynomolgus | Biotinylated Cynomolgus CD79B Protein, His,Avitag™ |  |
|
|
| CDB-C52H3 | Cynomolgus | Cynomolgus CD79B Protein, His Tag (MALS verified) |  |
|
|
| CDB-H52H3 | Human | Human CD79B Protein, His Tag (MALS verified) |  |
|
|
| CDB-H82E3 | Human | Biotinylated Human CD79B Protein, His,Avitag™ (MALS verified) |  |
|
|
| CDB-M52H3 | Mouse | Mouse CD79B Protein, His Tag (MALS verified) |  |
|
|
| CDB-M5253 | Mouse | Mouse CD79B Protein, Fc Tag (MALS verified) |  |
|
|
| CDB-M52H4 | Mouse | Mouse CD79B Protein, His Tag, low endotoxin (MALS verified) |  |
|
|
| CDB-H5259 | Human | Human CD79B Protein, Fc Tag |  |
|
|
Immobilized Biotinylated Human CD79B, His,Avitag (Cat. No. CDB-H82E3) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-CD79B (Polatuzumab) Humanized Antibody with a linear range of 0.1-2 ng/mL (Routinely tested).
The purity of Cynomolgus CD79B, His Tag (Cat. No. CDB-C52H3) is more than 90% and the molecular weight of this protein is around 20-40 kDa verified by SEC-MALS.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Polatuzumab vedotin | RG-7596; RO-5541077-000; FCU-2711; DCDS-4501A; RO-5541077 | Approved | Seattle Genetics Inc, Genentech Inc | Polivy | Japan | Lymphoma, Large B-Cell, Diffuse | F. Hoffmann-La Roche Ag | 2019-06-10 | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| NBT-508 | Phase 1 Clinical | Newbio Therapeutics Inc | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details | |
| Iladatuzumab vedotin | DCDS-0780A; RO-7032005 | F. Hoffmann-La Roche Ltd | Details | ||
| TolDCB29 | Phase 2 Clinical | Umc Utrecht | Arthritis, Rheumatoid | Details | |
| CD19/79b Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR CD19/79b | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell | Details |
| PRV-3279 | MGD-010; PRV-3279; CD32BxCD79B | Phase 2 Clinical | Macrogenics Inc | Drug-Related Side Effects and Adverse Reactions | Details |
This web search service is supported by Google Inc.
A-Z
